Vir Biotechnology
About: Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Employees: 587
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
15% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 67
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
2.17% less ownership
Funds ownership: 66.29% [Q2] → 64.12% (-2.17%) [Q3]
9% less funds holding
Funds holding: 215 [Q2] → 195 (-20) [Q3]
18% less capital invested
Capital invested by funds: $803M [Q2] → $656M (-$146M) [Q3]
48% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 42
86% less call options, than puts
Call options by funds: $1.28M | Put options by funds: $8.95M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
159%
upside
Avg. target
$52
604%
upside
High target
$110
1,399%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target | 1,399%upside $110 | Buy Reiterated | 20 Nov 2024 |
Needham Joseph Stringer 31% 1-year accuracy 39 / 127 met price target | 159%upside $19 | Buy Reiterated | 20 Nov 2024 |
Barclays Gena Wang 13% 1-year accuracy 4 / 30 met price target | 254%upside $26 | Overweight Maintained | 4 Nov 2024 |
Financial journalist opinion
Based on 6 articles about VIR published over the past 30 days
Neutral
Business Wire
3 days ago
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days. About.
Positive
Seeking Alpha
1 week ago
Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is similar to VIR-5500, in prostate cancer. As for elebsiran and tobevibart, two treatments for hepatitis B and hepatitis delta, a phase 3 program in hepatitis delta will get underway in H1'25.
Neutral
Business Wire
1 week ago
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AAS.
Positive
Investors Business Daily
2 weeks ago
Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients
Shares of Janux Therapeutics skyrocketed Tuesday on "unprecedented" results for an experimental prostate cancer treatment. The post Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients appeared first on Investor's Business Daily.
Neutral
Business Wire
3 weeks ago
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN™ platform on January 8, 2025, at 5:00 a.m. PT / 8:00 a.m. ET. A live webcast will be available on https://investors.vir.bio/.
Neutral
Business Wire
3 weeks ago
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and wil.
Neutral
Business Wire
1 month ago
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, in people with chronic hepatitis delta (CHD). The most-advanced and potential first-of-its-kind investigational human monoclonal antibody and siRNA combination dosed monthly achieved 100% virologic response and rapid hepatitis delta virus (HDV) RNA suppression. HDV RNA below the lower limit o.
Neutral
Business Wire
1 month ago
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at A.
Neutral
Business Wire
1 month ago
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg (
Positive
Seeking Alpha
1 month ago
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and partnered with Sanofi to leverage its PRO-XTEN platform for T-cell engagers. The strategic shift includes a 25% workforce reduction, saving $50 million annually by 2025, and focuses on advancing hepatitis delta and B treatments.
Charts implemented using Lightweight Charts™